当前蛋白身份:P09467 重新检索
本组结构的主要差异维度
构建体不同 突变/修饰不同 组装状态不同 配体/离子不同 实验环境不同 结构质量指标不同

差异标签只比较当前检索结果;所有PDB和assembly原始记录仍分别保留。

相关结构差异明细

一行代表一个 PDB 条目中的一个 biological assembly;同一蛋白的多个单体会分别列出。

PDB 条目 Assembly / 聚集状态 构建体 突变与修饰 配体、离子与非聚合物 实验方法 实验环境 结构质量
1FTA FRUCTOSE-1,6-BISPHOSPHATASE(D-FRUCTOSE-1,6-BISPHOSPHATE, 1-PHOSPHOHYDROLASE) (E.C.3.1.3.11) COMPLEXED WITH THE ALLOSTERIC INHIBITOR AMP 提交 1993-09-27 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 1–337(337 aa)
链 B 1–337(337 aa)
链 C 1–337(337 aa)
链 D 1–337(337 aa)
未记录 AMP ADENOSINE MONOPHOSPHATE × 4 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 2.30 Å
2JJK FRUCTOSE-1,6-BISPHOSPHATASE(D-FRUCTOSE-1,6-BISPHOSPHATE -1- PHOSPHOHYDROLASE) (E.C.3.1.3.11) COMPLEXED WITH A DUAL BINDING AMP SITE INHIBITOR 提交 2008-04-09 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 1–338(338 aa)
链 B 1–338(338 aa)
链 C 1–338(338 aa)
链 D 1–338(338 aa)
未记录 R15 N,N'-(heptane-1,7-diyldicarbamoyl)bis(3-chlorobenzenesulfonamide) × 2 X-RAY DIFFRACTION
X-ray结晶条件 RESERVOIR = 0.1M HEPES PH7.0, 0.1M AMMONIUM ACETATE, 12% PEG 3350
分辨率 2.00 Å R-free 0.266
2VT5 FRUCTOSE-1,6-BISPHOSPHATASE(D-FRUCTOSE-1,6-BISPHOSPHATE -1- PHOSPHOHYDROLASE) (E.C.3.1.3.11) COMPLEXED WITH A DUAL BINDING AMP SITE INHIBITOR 提交 2008-05-09 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 1–338(338 aa)
链 B 1–338(338 aa)
链 C 1–338(338 aa)
链 D 1–338(338 aa)
未记录 ROK 4-AMINO-N-[(2-SULFANYLETHYL)CARBAMOYL]BENZENESULFONAMIDE × 4 X-RAY DIFFRACTION
X-ray结晶条件 RESERVOIR = 0.1M HEPES, PH7.0, 0.1M AMMONIUM ACETATE, 12% PEG 3350
分辨率 2.20 Å R-free 0.247
2VT5 FRUCTOSE-1,6-BISPHOSPHATASE(D-FRUCTOSE-1,6-BISPHOSPHATE -1- PHOSPHOHYDROLASE) (E.C.3.1.3.11) COMPLEXED WITH A DUAL BINDING AMP SITE INHIBITOR 提交 2008-05-09 Assembly 2 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 E 1–338(338 aa)
链 F 1–338(338 aa)
链 G 1–338(338 aa)
链 H 1–338(338 aa)
未记录 ROK 4-AMINO-N-[(2-SULFANYLETHYL)CARBAMOYL]BENZENESULFONAMIDE × 4 X-RAY DIFFRACTION
X-ray结晶条件 RESERVOIR = 0.1M HEPES, PH7.0, 0.1M AMMONIUM ACETATE, 12% PEG 3350
分辨率 2.20 Å R-free 0.247
2WBB FRUCTOSE-1,6-BISPHOSPHATASE(D-FRUCTOSE-1,6-BISPHOSPHATE-1- PHOSPHOHYDROLASE) (E.C.3.1.3.11) COMPLEXED WITH AN AMP SITE INHIBITOR 提交 2009-02-26 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 1–338(338 aa)
链 B 1–338(338 aa)
链 C 1–338(338 aa)
链 D 1–338(338 aa)
未记录 RO3 N-{[(2Z)-5-BROMO-1,3-THIAZOL-2(3H)-YLIDENE]CARBAMOYL}-4-METHYLBENZENESULFONAMIDE × 4 X-RAY DIFFRACTION
X-ray结晶条件 0.1M AMMONIUM ACETATE 0.1M HEPES PH7 25% PEG 3350
分辨率 2.22 Å R-free 0.248
2WBB FRUCTOSE-1,6-BISPHOSPHATASE(D-FRUCTOSE-1,6-BISPHOSPHATE-1- PHOSPHOHYDROLASE) (E.C.3.1.3.11) COMPLEXED WITH AN AMP SITE INHIBITOR 提交 2009-02-26 Assembly 2 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 E 1–338(338 aa)
链 F 1–338(338 aa)
链 G 1–338(338 aa)
链 H 1–338(338 aa)
未记录 RO3 N-{[(2Z)-5-BROMO-1,3-THIAZOL-2(3H)-YLIDENE]CARBAMOYL}-4-METHYLBENZENESULFONAMIDE × 4 X-RAY DIFFRACTION
X-ray结晶条件 0.1M AMMONIUM ACETATE 0.1M HEPES PH7 25% PEG 3350
分辨率 2.22 Å R-free 0.248
2WBD FRUCTOSE-1,6-BISPHOSPHATASE(D-FRUCTOSE-1,6-BISPHOSPHATE-1- PHOSPHOHYDROLASE) (E.C.3.1.3.11) COMPLEXED WITH AN AMP SITE INHIBITOR 提交 2009-02-26 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 1–338(338 aa)
链 B 1–338(338 aa)
链 C 1–338(338 aa)
链 D 1–338(338 aa)
未记录 RO5 N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]-3-ethylbenzenesulfonamide × 4 X-RAY DIFFRACTION
X-ray结晶条件 0.1M AMMONIUM ACETATE, 0.1M HEPES PH 7.0, 15% PEG 3350
分辨率 2.40 Å R-free 0.277
2WBD FRUCTOSE-1,6-BISPHOSPHATASE(D-FRUCTOSE-1,6-BISPHOSPHATE-1- PHOSPHOHYDROLASE) (E.C.3.1.3.11) COMPLEXED WITH AN AMP SITE INHIBITOR 提交 2009-02-26 Assembly 2 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 E 1–338(338 aa)
链 F 1–338(338 aa)
链 G 1–338(338 aa)
链 H 1–338(338 aa)
未记录 RO5 N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]-3-ethylbenzenesulfonamide × 4 X-RAY DIFFRACTION
X-ray结晶条件 0.1M AMMONIUM ACETATE, 0.1M HEPES PH 7.0, 15% PEG 3350
分辨率 2.40 Å R-free 0.277
2Y5K Orally active aminopyridines as inhibitors of tetrameric fructose 1,6- bisphosphatase 提交 2011-01-14 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 1–338(338 aa)
链 B 1–338(338 aa)
链 C 1–338(338 aa)
链 D 1–338(338 aa)
未记录 YCU 1-[5-(2-METHOXYETHYL)-4-METHYL-THIOPHEN-2-YL]SULFONYL-3-[4-METHOXY-6-(METHYLCARBAMOYLAMINO)PYRIDIN-2-YL]UREA × 4 X-RAY DIFFRACTION
X-ray结晶条件 RESERVOIR: 0.1M HEPES, PH 7.0, 0.1 M AMMONIUM ACETATE, 12% PEG 3350.
分辨率 2.10 Å R-free 0.296
2Y5L orally active aminopyridines as inhibitors of tetrameric fructose 1,6- bisphosphatase 提交 2011-01-14 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 1–338(338 aa)
链 B 1–338(338 aa)
链 C 1–338(338 aa)
链 D 1–338(338 aa)
未记录 RO8 N-{[(2Z)-5-bromo-1,3-thiazol-2(3H)-ylidene]carbamoyl}-3-chlorobenzenesulfonamide × 4 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 2.20 Å R-free 0.254
2Y5L orally active aminopyridines as inhibitors of tetrameric fructose 1,6- bisphosphatase 提交 2011-01-14 Assembly 2 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 E 1–338(338 aa)
链 F 1–338(338 aa)
链 G 1–338(338 aa)
链 H 1–338(338 aa)
未记录 RO8 N-{[(2Z)-5-bromo-1,3-thiazol-2(3H)-ylidene]carbamoyl}-3-chlorobenzenesulfonamide × 4 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 2.20 Å R-free 0.254
3A29 Crystal structure of human liver FBPase in complex with tricyclic inhibitor 提交 2009-05-08 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 2–338(337 aa)
链 B 2–338(337 aa)
链 C 2–338(337 aa)
链 D 2–338(337 aa)
未记录 2T0 2-amino-4,5-dihydronaphtho[1,2-d][1,3]thiazol-8-yl dihydrogen phosphate × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 8.5;295 K;8-10% PEG 3350, 0.15M NaCl, 0.1M Tris/HCl, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
分辨率 2.60 Å R-free 0.247
3A29 Crystal structure of human liver FBPase in complex with tricyclic inhibitor 提交 2009-05-08 Assembly 2 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 2–338(337 aa)
链 B 2–338(337 aa)
未记录 2T0 2-amino-4,5-dihydronaphtho[1,2-d][1,3]thiazol-8-yl dihydrogen phosphate × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 8.5;295 K;8-10% PEG 3350, 0.15M NaCl, 0.1M Tris/HCl, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
分辨率 2.60 Å R-free 0.247
3A29 Crystal structure of human liver FBPase in complex with tricyclic inhibitor 提交 2009-05-08 Assembly 3 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 2–338(337 aa)
链 C 2–338(337 aa)
未记录 2T0 2-amino-4,5-dihydronaphtho[1,2-d][1,3]thiazol-8-yl dihydrogen phosphate × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 8.5;295 K;8-10% PEG 3350, 0.15M NaCl, 0.1M Tris/HCl, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
分辨率 2.60 Å R-free 0.247
3A29 Crystal structure of human liver FBPase in complex with tricyclic inhibitor 提交 2009-05-08 Assembly 4 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 2–338(337 aa)
链 D 2–338(337 aa)
未记录 2T0 2-amino-4,5-dihydronaphtho[1,2-d][1,3]thiazol-8-yl dihydrogen phosphate × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 8.5;295 K;8-10% PEG 3350, 0.15M NaCl, 0.1M Tris/HCl, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
分辨率 2.60 Å R-free 0.247
3A29 Crystal structure of human liver FBPase in complex with tricyclic inhibitor 提交 2009-05-08 Assembly 5 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 C 2–338(337 aa)
链 D 2–338(337 aa)
未记录 2T0 2-amino-4,5-dihydronaphtho[1,2-d][1,3]thiazol-8-yl dihydrogen phosphate × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 8.5;295 K;8-10% PEG 3350, 0.15M NaCl, 0.1M Tris/HCl, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
分辨率 2.60 Å R-free 0.247
3KBZ Crystal structure of human liver FBPase in complex with tricyclic inhibitor 6 提交 2009-10-20 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 2–338(337 aa)
链 B 2–338(337 aa)
链 C 2–338(337 aa)
链 D 2–338(337 aa)
未记录 2T4 {[(2-amino-8H-indeno[1,2-d][1,3]thiazol-4-yl)oxy]methyl}phosphonic acid × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 8.5;295 K;8-10% PEG 3350, 0.15M NaCl, 0.1M Tris/HCl, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
分辨率 2.45 Å R-free 0.275
3KC0 Crystal structure of human liver FBPase in complex with tricyclic inhibitor 10b 提交 2009-10-20 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 2–338(337 aa)
链 B 2–338(337 aa)
链 C 2–338(337 aa)
链 D 2–338(337 aa)
未记录 2T5 [(8H-indeno[1,2-d][1,3]thiazol-4-yloxy)methyl]phosphonic acid × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 8.5;295 K;8-10% PEG 3350, 0.15M NaCl, 0.1M Tris/HCl, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
分辨率 2.80 Å R-free 0.254
3KC1 Crystal structure of human liver FBPase in complex with tricyclic inhibitor 19a 提交 2009-10-20 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 2–338(337 aa)
链 B 2–338(337 aa)
链 C 2–338(337 aa)
链 D 2–338(337 aa)
未记录 2T6 {[(7-carbamoyl-8H-indeno[1,2-d][1,3]thiazol-4-yl)oxy]methyl}phosphonic acid × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 8.5;295 K;8-10% PEG 3350, 0.15M NaCl, 0.1M Tris/HCl, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
分辨率 2.25 Å R-free 0.262
4MJO Human liver fructose-1,6-bisphosphatase(d-fructose-1,6-bisphosphate, 1-phosphohydrolase) (e.c.3.1.3.11) complexed with the allosteric inhibitor 3 提交 2013-09-04 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 1–338(338 aa)
链 B 1–338(338 aa)
链 C 1–338(338 aa)
链 D 1–338(338 aa)
未记录 2C1 N-({4-bromo-6-[(methylcarbamoyl)amino]pyridin-2-yl}carbamoyl)-5-(2-methoxyethyl)-4-methylthiophene-2-sulfonamide × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;300 K;0.1 M ammonium acetate and 12% polyethylenglycol 3350 in 0.1 M HEPES, pH 7, VAPOR DIFFUSION, SITTING DROP, temperature 300K
分辨率 2.40 Å R-free 0.236
4MJO Human liver fructose-1,6-bisphosphatase(d-fructose-1,6-bisphosphate, 1-phosphohydrolase) (e.c.3.1.3.11) complexed with the allosteric inhibitor 3 提交 2013-09-04 Assembly 2 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 E 1–338(338 aa)
链 F 1–338(338 aa)
链 G 1–338(338 aa)
链 H 1–338(338 aa)
未记录 2C1 N-({4-bromo-6-[(methylcarbamoyl)amino]pyridin-2-yl}carbamoyl)-5-(2-methoxyethyl)-4-methylthiophene-2-sulfonamide × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;300 K;0.1 M ammonium acetate and 12% polyethylenglycol 3350 in 0.1 M HEPES, pH 7, VAPOR DIFFUSION, SITTING DROP, temperature 300K
分辨率 2.40 Å R-free 0.236
5LDZ Quadruple space group ambiguity due to rotational and translational non-crystallographic symmetry in human liver fructose-1,6-bisphosphatase 提交 2016-06-29 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 1–338(338 aa)
链 B 1–338(338 aa)
链 C 1–338(338 aa)
链 D 1–338(338 aa)
未记录 ZN ZINC ION × 6 SO4 SULFATE ION × 20 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 8.5;295 K;0.1 M Tris-HCl pH 8.5, 2 M (NH4)2SO4
分辨率 2.20 Å R-free 0.239
5LDZ Quadruple space group ambiguity due to rotational and translational non-crystallographic symmetry in human liver fructose-1,6-bisphosphatase 提交 2016-06-29 Assembly 2 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 E 1–338(338 aa)
链 F 1–338(338 aa)
未记录 ZN ZINC ION × 6 SO4 SULFATE ION × 18 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 8.5;295 K;0.1 M Tris-HCl pH 8.5, 2 M (NH4)2SO4
分辨率 2.20 Å R-free 0.239
6LW2 The N-arylsulfonyl-indole-2-carboxamide-based inhibitors against fructose-1,6-bisphosphatase 提交 2020-02-07 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 1–338(338 aa)
链 B 1–338(338 aa)
链 C 1–338(338 aa)
链 D 1–338(338 aa)
未记录 EW0 7-chloranyl-4-[(3-methoxyphenyl)amino]-N-(4-methoxyphenyl)sulfonyl-1-methyl-indole-2-carboxamide × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;291 K;0.2M Ammonium acetate, 0.1M HEPES, 20% PEG 3350, pH 7.0
分辨率 2.40 Å R-free 0.290
7C9Q Crystal structure of Human liver fructose-1,6-bisphoaphatase complex with Mg2+ and AMP 提交 2020-06-07 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 1–338(338 aa)
链 B 1–338(338 aa)
链 C 1–338(338 aa)
链 D 1–338(338 aa)
未记录 AMP ADENOSINE MONOPHOSPHATE × 4 MG MAGNESIUM ION × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;289 K;50mM Hepes pH 7.2, 150mM Sodium chloride, 8% (w/v) PEG 8000
分辨率 1.88 Å R-free 0.219
7CVH Human Fructose-1,6-bisphosphatase 1 in complex with geranylgeranyl diphosphate 提交 2020-08-26 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 1–338(338 aa)
链 B 1–338(338 aa)
链 C 1–338(338 aa)
链 D 1–338(338 aa)
未记录 FBP 1,6-di-O-phosphono-beta-D-fructofuranose × 4 MG MAGNESIUM ION × 8 AMP ADENOSINE MONOPHOSPHATE × 4 GRG GERANYLGERANYL DIPHOSPHATE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7.5;291 K;28% (v/v) polyethylene glycol 600, 0.1M HEPES
分辨率 2.09 Å R-free 0.218
7CVN The N-arylsulfonyl-indole-2-carboxamide-based inhibitors against fructose-1,6-bisphosphatase 提交 2020-08-26 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 1–338(338 aa)
链 B 1–338(338 aa)
链 C 1–338(338 aa)
链 D 1–338(338 aa)
未记录 GJO 4-(3-acetamidophenyl)-N-(4-methoxyphenyl)sulfonyl-7-nitro-1H-indole-2-carboxamide × 4 FBP 1,6-di-O-phosphono-beta-D-fructofuranose × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;291 K;0.2M Ammonium acetate, 0.1M HEPES, 20% PEG 3350, pH 7.0
分辨率 2.75 Å R-free 0.234
7CWE Human Fructose-1,6-bisphosphatase 1 in APO R-state 提交 2020-08-28 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 1–338(338 aa)
链 B 1–338(338 aa)
未记录 MG MAGNESIUM ION × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7.5;291 K;0.05 M cadmium sulfate, 0.1 M HEPES, pH 7.5, 1 M sodium acetate
分辨率 3.00 Å R-free 0.296
7EZF Indole-2-carboxylic acid derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase 提交 2021-06-01 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 1–338(338 aa)
链 B 1–338(338 aa)
链 C 1–338(338 aa)
链 D 1–338(338 aa)
未记录 0KI 7-chloranyl-5-ethyl-3-(3-hydroxy-3-oxopropyl)-1H-indole-2-carboxylic acid × 4 FBP 1,6-di-O-phosphono-beta-D-fructofuranose × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291 K;0.2M Ammonium acetate, 0.1M HEPES, 20% PEG 3350, pH 7.0
分辨率 2.76 Å R-free 0.236
7EZP Indole-2-carboxylic acid derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase 提交 2021-06-01 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 1–338(338 aa)
链 B 1–338(338 aa)
链 C 1–338(338 aa)
链 D 1–338(338 aa)
未记录 FBP 1,6-di-O-phosphono-beta-D-fructofuranose × 4 0GI 3-(3-hydroxy-3-oxopropyl)-5-(2-methylpropyl)-7-nitro-1H-indole-2-carboxylic acid × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291 K;0.2M Ammonium acetate, 0.1M HEPES, 20% PEG 3350, pH 7.0
分辨率 2.80 Å R-free 0.256
7EZR Indole-2-carboxylic acid derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase 提交 2021-06-01 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 1–338(338 aa)
链 B 1–338(338 aa)
链 C 1–338(338 aa)
链 D 1–338(338 aa)
未记录 0H1 5-ethyl-7-nitro-3-[3-oxidanylidene-3-(thiophen-2-ylsulfonylamino)propyl]-1H-indole-2-carboxylic acid × 4 FBP 1,6-di-O-phosphono-beta-D-fructofuranose × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;291 K;0.2M Ammonium acetate, 0.1M HEPES, 20% PEG 3350, pH 7.0
分辨率 3.27 Å R-free 0.253
7WVB Human Fructose-1,6-bisphosphatase 1 mutant R50A in APO R-state 提交 2022-02-10 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 1–338(338 aa)
链 B 1–338(338 aa)
链 C 1–338(338 aa)
链 D 1–338(338 aa)
突变:R50A 突变:R50A 突变:R50A 突变:R50A 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 6.5;293.15 K;0.1M BIS-Tris(pH 6.5), 20% PEGMME 5000, 2.5% sucrose
分辨率 2.09 Å R-free 0.233
9XV1 Crystal Structure of Fructose-1,6-bisphosphatase Complexed with a Covalent Inhibitor 提交 2025-11-25 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 1–336(336 aa)
链 B 1–336(336 aa)
链 C 1–336(336 aa)
链 D 1–336(336 aa)
未记录 A1E1G 2-bromanyl-~{N}-[2-[4-[(3-phenylphenyl)carbamoylsulfamoyl]phenyl]ethyl]ethanamide × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;291 K;0.1 M Tris (pH 8.8), 15% (v/v) EtOH
分辨率 1.96 Å R-free 0.213